Strides Pharma Consolidates European Business-to-Business Operations in Switzerland

29.11.2024 11:30:00 CET | news aktuell GmbH | Press release

Share
  • Market proximity of Strides Pharma International AG, based in Zug, Switzerland, opens the way for rapid technology transfer and innovation within the European market
  • Oren Weininger, longstanding leader at Fairmed Healthcare, heads the business as CEO and Chairman of the Board
Oren Weininger, CEO Copyright Strides Pharma International AG.
Oren Weininger, CEO Copyright Strides Pharma International AG.

Zug, Switzerland. Strides Pharma Science Limited, globally recognized as a leading pharmaceutical company operating across 100 countries and headquartered in Bangalore, India, is consolidating its European business through Strides Pharma International AG, based in Zug, Switzerland.

Strides Pharma specializes in the development and manufacturing of IP-led niche finished dosage formulations. With over three decades of research and development expertise, Strides Pharma continuously develops and delivers products with innovative and improved technologies at competitive prices. Notably, Strides Pharma is among the world's largest manufacturers of Ibuprofen and Macrogol in various forms. Their unique range of drug delivery technologies opens up versatile and lucrative opportunities within the ever-evolving target markets.

The partner-centric in-licensing portfolio of over 250 formulations is consolidated in synergICE as a one-stop shop. It includes generics, sterile injectables and value-added products, Women´s Health hormones, lyophilized orally dissolving tablets and end-to-end biopharmaceutical CDMO services.

Oren Weininger, newly appointed Chairman of the Board, stated, “With this strengthened European B2B presence, we can respond faster to our customers’ needs and provide flexible, innovative solutions, and interesting generic portfolio, including comprehensive support in supply chain & quality management and regulatory processes by Strides Pharma International and the EU GMP-site in Hamburg, Germany.”

Key Markets are Central and Southern Europe (especially Germany), Scandinavia, Benelux and the Visegrád countries.

For further information, please visit: www.fair-med.com/newsroom

Contact Agency What About Now, Andreas Schöpf
as@whataboutnow.de Tel. +49 160 90723690

Following his roles at Dexcel Pharma and Kamedis, Oren Weininger took the position of CEO at Fairmed Healthcare AG in 2014 and subsequently became owner in 2018. Strides Pharma, after a period of successful partnership, invested in the company in 2019, further bolstering leading Fairmed Healthcare product lines. In addition to being appointed Chairman of the Board of Strides Pharma International AG, Weininger continues to lead Fairmed Healthcare GmbH in Hamburg.

Strides Pharma Science Limited, headquartered in Bangalore, India, was incorporated in 1990. The company has a global manufacturing footprint with eight facilities spread across four continents and a strong presence in 100 countries. Strides Pharma is a key active pharmaceutical ingredient manufacturer and producer of various products; every fourth Ibuprofen tablet on the global market today is supplied by Strides Pharma.

Images

Oren Weininger, CEO Copyright Strides Pharma International AG.
Oren Weininger, CEO Copyright Strides Pharma International AG.
Download

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

HEIDELBERG systematically pressing ahead with strategic development – solid start to FY 2026/202719.8.2026 09:02:17 CEST | Press release

Taking over manroland sheetfed lifecycle business and POLAR production operations strengthens core business ONBERG pursuing partnership with Skyeton in European defense sector Move into production of sodium-ion battery storage systems taps into new potential First-quarter incoming orders lay solid foundation for further business development Sales and EBITDA margin at start of year in line with expectations Forecast for financial year 2026/2027 confirmed

Polarise secures further debt financing to expand its European AI cloud platform18.8.2026 11:47:20 CEST | Press release

Düsseldorf, 18. August 2026 – Polarise Holding GmbH (“Polarise”), a European provider of sovereign AI cloud solutions, has secured a debt financing partnership with SWI Stoneweg Icona Group (“SWI Group”) to accelerate the expansion of its European AI cloud platform. The financing of up to a high double-digit million-euro amount strengthens Polarise’s funding base for the continued execution of its growth strategy. As part of the new financing structure, Polarise and SWI Group have agreed to transition the previously announced majority equity investment agreement into a debt financing arrangement. Michel Boutouil, CEO of Polarise, said: “Our growth strategy is aimed at building Europe’s AI infrastructure of the future – with sustainable, highly efficient AI Factories and sovereign AI compute for businesses. We are executing this strategy with significant momentum and strong partners. Polarise develops and operates AI data centres – so-called AI Factories – in Germany and across Europe.

CHRIST chooses fulfillmenttools and commercetools for a future-proof commerce architecture31.7.2026 12:47:56 CEST | Press release

Cologne – CHRIST Juweliere und Uhrmacher, one of Europe's most renowned jewelry retailers, is partnering with fulfillmenttools to transform the way it manages and orchestrates orders across its retail network. CHRIST is implementing the Agentic Order Management System (OMS) – as part of a broader transformation in which the retailer is building a modular, future-proof commerce architecture powered by commercetools Sphere, the autonomous commerce platform. The new system landscape spans stores and digital channels across Germany, Austria and the Netherlands. Breaking free from monolithic constraints For internationally operating retailers, the ability to respond flexibly and quickly to customer demand is a key success factor. This is especially true in the jewellery trade, which is shaped by specific requirements: high-value products, complex inventory structures, and customers who expect a first-class, seamless shopping experience at every touchpoint. CHRIST has built a strong operatio

Bikeleasing Group announces strategic investment in New Zealand’s leading bike leasing company Workride / Next strategic step in cross-continental expansion29.7.2026 14:18:02 CEST | Press release

The Bikeleasing Group announces strategic investment in Workride, New Zealand’s market leader for company bike leasing as an employee benefit. Around 2,000 New Zealand employers already use Workride’s offering. The investment extends the Bikeleasing Group’s international presence and marks its next cross-continental step in its growth trajectory.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye